Amgen plans to open a Science and Innovation Center in Genome Valley, Hyderabad, expanding the biotechnology company’s global research and development network and adding scientific capabilities in India.
The new center is expected to begin operating in 2027 and will become part of Amgen’s worldwide R&D organization, which includes seven research laboratories. The facility will bring together scientists and technologists working in discovery chemistry, drug metabolism and pharmacokinetics, and precision medicine.
Amgen said the center will strengthen its efforts to integrate experimental science with data and digital innovation, with the goal of accelerating the discovery and development of medicines for patients globally. The company said the site will work closely with its research locations around the world to improve the speed, precision and efficiency of drug development.
Jay Bradner, Amgen’s executive vice president of research and development, artificial intelligence and data, said the center will expand how the company combines laboratory science, technology and data across its global research capabilities. He said the Hyderabad facility complements Amgen’s established U.S.-based R&D footprint.
The Genome Valley center will complement Amgen’s existing technology and innovation site in Hyderabad. Together, the locations are expected to enable closer integration between wet-laboratory research and technology capabilities as the company works to advance medicine development.
Som Chattopadhyay, Amgen’s senior vice president of Global Business Solutions and national executive, said India will play an important role in the company’s global R&D network. He said the new site will promote scientific collaboration and allow Amgen to participate more deeply in the local innovation ecosystem.
Naveen Gullapalli, managing director of Amgen India, said Hyderabad’s life-sciences sector and STEM talent base will support the application of advanced technologies at scale. He said the center will combine biotechnology and digital innovation to help serve more patients worldwide.
Telangana Information Technology and Industries Minister D. Sridhar Babu said Amgen’s decision reflects Hyderabad’s growing position as a global research hub. He said the region aims to build on its pharmaceutical and vaccine capabilities by becoming a location where new medicines and therapies can be discovered, developed and brought to global markets.
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox!
Sign up now!